Search results for "RESPIRATORY"

showing 10 items of 5091 documents

Accelerated telomere attrition in children and teenagers with α1-antitrypsin deficiency.

2016

Numerous studies have shown that oxidative stress accelerates telomere shortening in several lung pathologies. Since oxidative stress is involved in the pathophysiology of α1-antitrypsin deficiency (AATD), we hypothesised that telomere shortening would be accelerated in AATD patients. This study aimed to assess telomere length in AATD patients and to study its association with α1-antitrypsin phenotypes.Telomere length, telomerase activity, telomerase reverse transcriptase (hTERT) expression and biomarkers of oxidative stress were measured in 62 children and teenagers (aged 2–18 years) diagnosed with AATD and 18 controls (aged 3–16 years).Our results show that intermediate-risk (MZ; SZ) and …

0301 basic medicinePulmonary and Respiratory MedicineOncologyMalemedicine.medical_specialtyTelomeraseAdolescentmedicine.disease_causeBody Mass Index03 medical and health sciencesInternal medicinealpha 1-Antitrypsin DeficiencymedicineHumansTelomerase reverse transcriptaseChildLungTelomeraseTelomere ShorteningAlpha 1-antitrypsin deficiencybusiness.industryCase-control studyTelomeremedicine.diseaseMolecular biologyPathophysiologyTelomereOxidative Stress030104 developmental biologyPhenotypeSpirometryCase-Control StudiesChild PreschoolBiomarker (medicine)FemalebusinessOxidative stress
researchProduct

Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q

2020

Epidermal growth factor receptor (EGFR) L718Q is a rare resistant mutation which independently leads to third-generation tyrosine kinase inhibitor (TKI) resistance. Although a few studies have examined its resistance mechanisms, no effective treatment strategy has yet been proposed for patients with this mutation. Here, we report an effective treatment strategy for the rare EGFR L718Q mutation for the first time. A 44-year-old Chinese male patient initially presented with the sensitizing EGFR L858R mutation, and the progression-free survival (PFS) time after initial icotinib treatment was 9 months. When the progression of the disease (PD) and the EGFR T790M mutation were identified, he did …

0301 basic medicinePulmonary and Respiratory MedicineOncologyiMDT Cornermedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentnon-small cell lung cancer (NSCLC)Tyrosine-kinase inhibitorTargeted therapy03 medical and health sciencesT790M0302 clinical medicineInternal medicinemedicineOsimertinibEpidermal growth factor receptorbiologybusiness.industrymedicine.disease030104 developmental biology030220 oncology & carcinogenesisMutation (genetic algorithm)Icotinibbiology.proteinbusiness
researchProduct

Lung Metastases from Esophageal Granular Cell Tumor: An Undoubted Criterion for Malignancy

2017

0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtyPathologyLung NeoplasmsEsophageal NeoplasmsMalignancy03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansNeoplasm MetastasisGranular cell tumorLungbusiness.industryMiddle Agedmedicine.disease030104 developmental biologymedicine.anatomical_structureOncologyGranular Cell Tumor030220 oncology & carcinogenesisEsophageal Granular Cell TumorFemalebusinessJournal of Thoracic Oncology
researchProduct

New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA

2017

Lung cancer is the second most frequent tumor and the leading cause of death by cancer in both men and women. Increasing knowledge about the cancer genome and tumor environment has led to a new setting in which morphological and molecular characterization is needed to treat patients in the most personalized way in order to achieve better outcomes. Since tumor products can be detected in body fluids, the liquid biopsy, particularly, peripheral blood, has emerged as a new source for lung cancer biomarker's analysis. A variety of tumor components can be used for this purpose. Among them, circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) should be especially considered. Different…

0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtybiologybusiness.industrynon-small cell lung cancer (NSCLC)CancerReview Articlemedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineCirculating tumor cellCell-free fetal DNA030220 oncology & carcinogenesisInternal medicineImmunologymedicinebiology.proteinBiomarker (medicine)Epidermal growth factor receptorLiquid biopsyLung cancerbusiness
researchProduct

P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC

2017

0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtybusiness.industry03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyAtezolizumab030220 oncology & carcinogenesisInternal medicineMedicineBiomarker (medicine)Erlotinibbusinessmedicine.drugJournal of Thoracic Oncology
researchProduct

MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC

2018

0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtybusiness.industry03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyAtezolizumab030220 oncology & carcinogenesisInternal medicinemedicineErlotinibLong term safetybusinessmedicine.drugJournal of Thoracic Oncology
researchProduct

Vaccine and immune cell therapy in non-small cell lung cancer

2018

Abstract: Despite new advances in therapeutics, lung cancer remains the first cause of mortality among different types of malignancies. To improve survival, different strategies have been developed such as chemotherapy combinations, targeted therapies and more recently immunotherapy. Immunotherapy is based on the capability of the immune system to differentiate cancer cells from normal cells to fight against the tumor. The two main checkpoint inhibitors that have been widely studied in non-small cell lung cancer (NSCLC) are PD-1/PD-L1 and CTLA-4. However, interactions between tumor and immune system are much more complex with several different elements that take part and probably many new i…

0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunotherapyReview Articlemedicine.diseaseClinical trialCell therapy03 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemAntigen030220 oncology & carcinogenesisInternal medicineCancer cellmedicineHuman medicineLung cancerbusinessAdjuvantJournal of thoracic disease
researchProduct

The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future?

2016

Exclusive chemoradiotherapy (CRT) delivering 50 Gy over 5 weeks with cisplatin and fluorouracil-based chemotherapy is a cornerstone in locally advanced esophageal cancer or non-operable patients since the results of the pivotal study of US Intergroup RTOG-8501 (1). This trial has successfully demonstrated that some patients with esophageal carcinoma may be long-term survivors so that this treatment is now definitely accepted as curative (2). Nevertheless the prognosis is still very disappointing with a 5-year overall survival rate of approximately 25%. Attempts to improve overall survival by escalating the dose of radiotherapy with concurrent cisplatin and fluorouracil has been assessed in …

0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtymedicine.medical_treatmentLocally advancedCetuximab[SDV.CAN]Life Sciences [q-bio]/CancerOutcomes[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract[ SDV.CAN ] Life Sciences [q-bio]/CancerIntensity-Modulated Radiotherapy03 medical and health sciences0302 clinical medicineInternal medicineCarcinomaMedicineComputingMilieux_MISCELLANEOUSCapecitabineCisplatinChemotherapybusiness.industryCarcinomaInduction ChemotherapyEsophageal cancermedicine.diseaseRadiation-Therapy3. Good healthRadiation therapyEditorial030104 developmental biologyChemoradiationFluorouracil030220 oncology & carcinogenesisIi Randomized-TrialCisplatinbusiness[ SDV.MHEP.PSR ] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractChemoradiotherapymedicine.drug
researchProduct

Functional characterization of a novel 3D model of the epithelial-mesenchymal trophic unit

2017

Background/Aim: Epithelial-mesenchymal communication plays a key role in tissue homeostasis and abnormal signaling contributes to chronic airways disease such as COPD. Most in vitro models are limited in complexity and poorly represent this epithelial-mesenchymal trophic unit. We postulated that cellular outgrowth from bronchial tissue would enable development of a mucosal structure that recapitulates better in vivo tissue architecture. Materials and Methods: Bronchial tissue was embedded in Matrigel and outgrowth cultures monitored using time-lapse microscopy, electrical resistance, light and electron microscopy. Cultures were challenged repetitively with cigarette smoke extract (CSE). Res…

0301 basic medicinePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyClinical BiochemistryBronchiRespiratory MucosaBiologyImmunofluorescenceModels Biologicalfibroblastbronchial03 medical and health sciencesIn vivoSmokemedicineHumansFibroblastMolecular BiologyCells CulturedTissue homeostasisMicroscopyMatrigelECMelectron microscopymedicine.diagnostic_testcigarette smokeMesenchymal stem cellEpithelial CellsMesenchymal Stem CellsEpitheliumCell biologyDrug Combinations030104 developmental biologymedicine.anatomical_structurein vitro modelMotile ciliumProteoglycansCollagenLamininepitheliumExperimental Lung Research
researchProduct

Heat shock protein: a hot topic in idiopathic pulmonary fibrosis

2017

HSP90 inhibition could be an exciting new treatment strategy for IPF http://ow.ly/HfKY306uvxw

0301 basic medicinePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyPulmonary Fibrosis03 medical and health sciencesIdiopathic pulmonary fibrosis0302 clinical medicineHeat shock proteinPulmonary fibrosismedicineHumansHeat-Shock Proteinsbiologybusiness.industrymedicine.diseaseImmunohistochemistryHsp90Idiopathic Pulmonary Fibrosis030104 developmental biology030228 respiratory systemImmunologybiology.proteinImmunohistochemistryTreatment strategybusinessEuropean Respiratory Journal
researchProduct